Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the second quarter of 2024.
- Cartesian Therapeutics reported earnings per share of 54 cents. This was above the analyst estimate for EPS of -$1.19.
- The company reported revenue of $33.45 million.
- This was 1,727.60% better than the analyst estimate for revenue of $1.83 million.